Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity

  • Bhat-Nakshatri P
  • Goswami C
  • Badve S
 et al. 
  • 70

    Readers

    Mendeley users who have this article in their library.
  • 34

    Citations

    Citations of this article.

Abstract

Recently developed genomics-based tools are allowing repositioning of Food and Drug Administration (FDA)-approved drugs as cancer treatments, which were employed to identify drugs that target cancer stem cells (CSCs) of breast cancer. Gene expression datasets of CSCs from six studies were subjected to connectivity map to identify drugs that may ameliorate gene expression patterns unique to CSCs. All-trans retinoic acid (ATRA) was negatively connected with gene expression in CSCs. ATRA reduced mammosphere-forming ability of a subset of breast cancer cells, which correlated with induction of apoptosis, reduced expression of SOX2 but elevated expression of its antagonist CDX2. SOX2/CDX2 ratio had prognostic relevance in CSC-enriched breast cancers. K-ras mutant breast cancer cell line enriched for CSCs was resistant to ATRA, which was reversed by MAP kinase inhibitors. Thus, ATRA alone or in combination can be tested for efficacy using SOX2, CDX2, and K-ras mutation/MAPK activation status as biomarkers of response.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Poornima Bhat-Nakshatri

  • Chirayu P. Goswami

  • Sunil Badve

  • George W. Sledge

  • Harikrishna Nakshatri

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free